The Achievements of the Beatson Pebble Appeal
Thanks to fantastic philanthropic support and donations from other sources, the University of Glasgow’s Wolfson Wohl Cancer Research Centre was opened in May 2014, in Bearsden, in Glasgow. Since then, the Centre’s team has made exciting and encouraging breakthroughs. The Centre is now internationally renowned and the research taking place there helps to make a very positive difference to the lives of patients living with cancer.
We are entering an exciting phase in the life of the University of Glasgow; the construction of new educational and research facilities on the former Western Infirmary site is about to begin. This ambitious undertaking will see the University's largest expansion programme since the relocation to Gilmorehill in the 1870s. This development will ensure the University can continue to make world-changing breakthroughs in numerous fields of science, including cancer, in the future.
We are approaching the 5th Anniversary of the Wolfson Wohl Centre, giving us a chance to celebrate the extent to which philanthropic donations have contributed to the successes the Centre to date.
Dr Harpal Kumar, who opened the Centre in 2014 said;
'While we have made huge strides in our fight against cancer over recent decades, the battle still rages and we need to keep investing in new research centres like this in order to make further progress. Glasgow is a major centre for cancer research in the UK and a key partner in our fight. Basic research like the kind that will take place in the Wolfson Wohl is essential to turning the knowledge gleaned in the lab into treatments that will actually help patients beat cancer. We’re delighted to see it up and running.”
The Aims of the Beatson Pebble Appeal
The campaign now aims to support the ongoing work of the Centre, to provide the most up-to-date facilities and equipment, and to continue to attract the best and the brightest to drive the vital work going on there.
By bringing the funds, facilities and people together, Glasgow will continue to be the home of groundbreaking developments in the understanding and treatment of cancer. The Beatson Pebble Appeal will continue to fundraise to make this ambition a reality, and transform the lives of future cancer patients.
And it is important to remember that funds raised in Glasgow, stay in Glasgow. We have no head office making decisions on our behalf. You can rest assured that any funds donated, will be transferred directly to the scientists working on breakthrough cancer treatments.
Research Aims- a Case for Pancreatic Cancer
Cancer affects 1 in 2 people in their lifetime in the UK. However, the death toll from three of the UK’s most common cancers- breast, bowel and male lung cancer- has dropped to its lowest level for almost 40 years. Sadly, the same cannot be said for pancreatic cancer; just over three per cent of pancreatic cancer patients survive for at least five years, only a fraction more than the two per cent who survived that long in the early 1970s. Every year, around 8,800 people are diagnosed with the disease and around 8,300 die from it.
Across all cancers, half of patients now survive at least twice that long. But most cases of pancreatic cancer go undetected until it is too late for surgery. And with the lack of effective tests and treatments for the disease, the majority of patients still die within a year.
Professor Andrew Biankin, Director of WWCRC, and a world-leader in pancreatic cancer research, moved to Glasgow in 2013 with a vision to revolutionise ways to treat pancreatic cancer. He and the team have recently received substantial funding to lead the PRECISION-Panc project, which will focus on matching patients to treatments most likely to work for their type of pancreatic cancer.
Because pancreatic cancer survival is poor, many patients are open to participating in clinical trials, but the aggressiveness of the disease poses a huge challenge. “It can take a long time to get patients through the current system and into a trial. By that time, it’s often too late, because the patient is no longer well enough.’
Matching patients and clinical trials is also known as precision medicine (also known as personalised medicine), and is a priority for the University of Glasgow’s College of Medical, Veterinary and Life Sciences. The University’s ambitious plans to redevelop the Western Infirmary site over the next decade will enable the College to remain at the forefront of global developments in precision medicine. Understanding how to provide the right treatment at the right time will transform the lives of patients and provide new opportunities to tackle the accelerating cost of chronic diseases.
On the 8th May this year, Professor Biankin was awarded a fellowship of the Academy of Medical Sciences, the independent body in the UK representing the diversity of medical science. Fellows are elected for their contribution to biomedical and health research, the generation of new knowledge in medical sciences and its translation into benefits to society.
Funds raised can be allocated to your chosen research area of interest, or to the medical opportunities in the Campus redevelopment. Find out more: http://www.gla.ac.uk/explore/campus/.